----item----
version: 1
id: {BA798D3E-DA1D-4DD2-AE28-ECDFC9F9FD8F}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/11/03/Par files for IPO
parent: {9A22D265-E46B-490A-8BDC-BA644F0271DB}
name: Par files for IPO
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 4b8c12d0-66b4-4fd8-9007-bda385ca593d

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{728904A1-7259-48E8-8256-60D002A0BFEA}|{C7FD764C-38F2-42BC-9F1A-A9864C90E18B}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 17

Par files for IPO
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 17

Par files for IPO
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1058

<p>Par Pharmaceutical has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of up to $100m. The Chestnut Ridge, New York company specializes in harder to make generics (or those that face complex regulatory challenges) and also has two branded specialty pharma products: the hormonal anticancer therapy Megace (megestrol acetate) and Nascobal (cyanocobalamin, USP) vitamin B<subscript>12</subscript> nasal spray. The company has not decided the size and timing of the offering, but it intends to use the proceeds primarily to pay down debt. In December 2014 long-term debt totalled $1.9bn. Revenues in 2014 were $1.3bn, and the firm booked a net loss of $106m. Last year it <a href="http://www.scripintelligence.com/policyregulation/Par-to-pay-100m-to-settle-Salix-patent-suit-354074" target="_new">agreed to pay $100m</a> to settle a patent dispute with Salix Pharmaceuticals over the latter's oral proton-pump inhibitor Zegerid, an immediate-release form of omeprazole plus sodium bicarbonate.</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 936

<p>Par Pharmaceutical has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of up to $100m. The Chestnut Ridge, New York company specializes in harder to make generics (or those that face complex regulatory challenges) and also has two branded specialty pharma products: the hormonal anticancer therapy Megace (megestrol acetate) and Nascobal (cyanocobalamin, USP) vitamin B<subscript>12</subscript> nasal spray. The company has not decided the size and timing of the offering, but it intends to use the proceeds primarily to pay down debt. In December 2014 long-term debt totalled $1.9bn. Revenues in 2014 were $1.3bn, and the firm booked a net loss of $106m. Last year it <a>agreed to pay $100m</a> to settle a patent dispute with Salix Pharmaceuticals over the latter's oral proton-pump inhibitor Zegerid, an immediate-release form of omeprazole plus sodium bicarbonate.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 17

Par files for IPO
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151103T150000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151103T150000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151103T150000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028130
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 17

Par files for IPO
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357230
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042311Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

4b8c12d0-66b4-4fd8-9007-bda385ca593d
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042311Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
